BHVN biohavenpharma.com: EV/EBITDA Multiple
Flawless delivery of neurological drugs guarantees patients stable access to therapy. The EV/EBITDA multiple trajectory confirms operational resilience, with the indicator currently at 0.00. Biohaven Ltd. maintains a foundation for growth through its status as a migraine treatment innovator and the retention of leading neurobiologists. The combination of physician trust and personnel stability within CNS laboratories provides Biohaven Ltd. with long-term development potential.
BHVN (biohavenpharma.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- company stock capitalization data:
- issuer book value statistics:
- debt and solvency information:
- financial results and valuation multiples details:
BHVN - Profit After Payment of Taxes|Projected Future Earnings Biohaven Ltd.|BHVN - Price to Earnings Multiple|Projected Price to Earnings Biohaven Ltd.|BHVN - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Biohaven Corp|BHVN - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Biohaven|BHVN - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months biohavenpharma.com|BHVN - Earnings per share growth in current year|Net earnings per share growth forecast for next year Biohaven Ltd.
Fundamental company valuation:Biohaven Pharmaceutical (BHVN)
Biohaven Ltd. (BHVN) transition toward new neurological developments amid volatile revenue necessitates a business valuation via EV/EBITDA, which correlates market capitalization and debt with operating profit before taxes, depreciation, and amortization. This calculation strips the valuation of debt burdens and tax distortions, allowing the EV/EBITDA business valuation level to determine the real value of assets and recognize a trend reversal in a timely manner.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Neurocrine Corp (NBIX) - Company Value to EBITDA|Regencell Bioscience - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation AXSM (axsome.com)|ACAD: EV/EBITDA Multiple|Xenon Pharmaceuticals Inc. (XENE) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio VKTX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SUPN|EV/EBITDA Multiple CPRX|DNLI - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|AMLX: Enterprise Value to Operating Income Before Depreciation|TRVI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation PRAX (Praxis Corp)|Anavex Life Sciences (AVXL) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CBLL (ceribell.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio PRTA|ALEC (Alector Therapeutics) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ANNX|omeros.com - Enterprise Value to Operating Income Before Depreciation|Neurogene Inc. - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio acimmune.com (ACIU)|Voyager Therapeutics, Inc. - EV/EBITDA Multiple|NMRA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SCLX: EV/EBITDA Multiple|Tevogen Bio Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio ACOG|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CGTX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inhibikase Therapeutics, Inc. (IKT)|Cassava Sciences Inc - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Assertio ASRT|COYA: Enterprise Value to Operating Income Before Depreciation|VistaGen Therapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals, Inc.) - Enterprise Value to EBITDA Ratio|CervoMed, Inc. (CRVO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Ltd.|CLNN: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PepGen Inc. (PEPG)|JUNS - Company Value to EBITDA|EV/EBITDA Multiple RLMD (Relmada Therapeutics, Inc.)|Annovis Bio Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Grace Tx - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Firefly Neuro AIFF|anewmeds.com (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA NeuroSense Therapeutics Ltd. (NRSN)|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - EV/EBITDA Multiple|MTVA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple NRXS|EV/EBITDA Multiple heliusmedical.com (HSDT)|Passage Bio - Enterprise Value to EBITDA Ratio|Neuphoria Therapeutics, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Minerva Neurosciences, Inc. - EV/EBITDA Multiple|Company Value to EBITDA Athira Pharma Inc|Addex Therapeutics, Ltd. (ADXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ALZN|Enterprise Value to EBITDA Ratio CYCN|PTIX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CRGT (cortigent.com)|Avenue Therapeutics, Inc - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio BCLI (BrainStorm Cell Therapeutics Inc.)|Cara Therapeutics, Inc. - EV/EBITDA Multiple|CHRO (chromocell.com) - Enterprise Value to Operating Income Before Depreciation|ELYM (eliemtx.com) - Enterprise Value to EBITDA Ratio|ITCI - Total Company Value to Operating Income Before Depreciation Ratio|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MRNS|EV/EBITDA Multiple NKGN|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|Sage Therapeutics - Enterprise Value to EBITDA Ratio|Synaptogenix Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VIGL (Vigil Neuroscience) - Enterprise Value to Operating Income Before Depreciation|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CERE
